Clicks Group holds margins amid WMS disruption and competition, guides 4-9% HEPS growth
Interim results show resilience through private label and pharmacy gains, but a warehouse system hiccup and rising fuel costs temper the outlook.
CLS.JO · Earnings Call · 2026-04-24
A Difficult Half, a Steady Hand
Clicks Group’s interim results for the six months ended February 2026 were a study in controlled turbulence. Group turnover grew 7.4%, retail sales rose 5.4%, and diluted headline earnings per share increased 8.1% to ZAR 6.53. Yet the numbers mask a period of self-inflicted pain: the rollout of a new warehouse management system (WMS) at the Western Cape distribution center disrupted peak trading, costing ZAR 175 million in sales—“The warehouse management system implementation at our Western Cape distribution center had a short-term impact of ZAR 175 million on sales.” — Gordon Traill, Chief Financial Officer · 2026-04-24 Management says the DC is now “working optimally,” but the episode underscores how operational execution can temporarily offset strategic strength.
Intensifying competition was the other headline. New entrants and traditional retailers pushing into health and beauty forced higher promotional activity. Yet the group’s trading margin held at 9.1%, a testament to a fortified private label portfolio and disciplined cost control. CEO Bertina Engelbrecht acknowledged the shifting landscape:
We have an African proverb that states, "if the drum beat changes, the dance must change."
Strategic Levers: GLP-1, Private Label, and Pharmacy
A key driver of resilience is the continuing surge in GLP-1 therapies. Engelbrecht noted: “The strong growth of GLP-1s is continuing with our extensive pharmacy network providing a clear competitive advantage.” — Bertina Engelbrecht, Chief Executive Officer · 2026-04-24 This growth, while supporting pharmacy footfall, has pressured the margin mix—a trade-off management accepts as it builds its wholesale and retail pharmacy ecosystem. The company’s private label, a defensive pillar, saw muted growth of 4.6% mainly due to the WMS impact, but strategic ranges like OptiHealth are being aggressively expanded. “The muted performance of private label and exclusives up 4.6% is because 60% of our bath and body sales are accounted for during the peak trading period when we were most impacted by the WMS implementation.” — Bertina Engelbrecht, Chief Executive Officer · 2026-04-24
Pharmacy remains the anchor, gaining market share to 24.9% despite licensing delays. The group opened its 800th pharmacy after the period and continues to expand UniCare and primary care clinics. Meanwhile, the completion of the LEAP pharmacy management system rollout is now being leveraged commercially—marketing the software to third parties is a new strategic angle, a direct evolution from earlier commitments (“By November, we will have completed the rollout of LEAP to all our pharmacies.” — Bertina Engelbrecht, Chief Executive Officer · 2025-10-23 from the prior call).
UPD Strength and Cost Pressures
UPD delivered a strong wholesale performance, with preferred bulk contracts up 31.1% and fuel cost savings from an aggressive EV fleet conversion now covering 86% of wholesale vehicles. Yet the loss of two bulk contracts and a lower SEP increase dragged the trading margin down 10 basis points. Distribution profitability remains under pressure, a point echoed by CFO Gordon Traill on the quarter’s spending discipline.
Fuel prices are a looming headwind. South Africa imports most of its oil, and rising diesel costs will ripple through transport and food prices. Management is mitigating via EVs, but the broader consumer squeeze is a concern. As Gordon Traill noted in the prior call, the GLP-1 opportunity is best captured when originators genericize (“GLP-1s have been growing very, very fast over the past 24 months.” — Gordon Traill, Chief Financial Officer · 2025-10-23)—a dynamic that could improve margins if portended.
Outlook and Leadership
The company guided to diluted HEPS growth of 4% to 9% for the full year, a cautious range reflecting geopolitical uncertainty—particularly the Middle East—that could drive inflation and interest rates. The guidance is also conservative given the ongoing WMS implementation lessons and the need to reduce elevated inventory (89 days) without markdown risk.
On leadership, Bertina Engelbrecht confirmed she will stay until August 2028, with a Nominations Committee already working on succession. This stability provides continuity as the retailer pilots on-demand OTC delivery, reworks its ClubCard loyalty mechanics, and tests smaller concept stores. The month-to-month cashback change appears to have lifted customer engagement, though management is selective about promotional intensity to protect margins.
Clicks Group is navigating a tricky period with credible execution. The full-year outlook is prudent, but the combination of pharmacy expansion, private label innovation, and UPD’s cost initiatives should underpin steady, if not spectacular, earnings growth.